CHMP recommends approval of Puma’s breast cancer drug Neratinib

This article was originally published here

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has reversed its stance on Puma Biotechnology’s breast cancer drug Neratinib by adopting a positive trend vote for its approval in the Europe.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply